scholarly journals Boosting phagocytosis and anti-inflammatory phenotype in microglia mediates neuroprotection by PPARγ agonist MDG548 in Parkinson's disease models

2018 ◽  
Vol 175 (16) ◽  
pp. 3298-3314 ◽  
Author(s):  
Daniela Lecca ◽  
Elzbieta Janda ◽  
Giovanna Mulas ◽  
Andrea Diana ◽  
Concetta Martino ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Disease Models ◽  
Pparγ Agonist ◽  
Inflammatory Phenotype ◽  
Anti Inflammatory

scholarly journals Pro-survival and anti-inflammatory roles of NF-κB c-Rel in the Parkinson's disease models

Redox Biology ◽  
2020 ◽  
Vol 30 ◽  
pp. 101427 ◽  
Author(s):  
Zishan Wang ◽  
Hongtian Dong ◽  
Jinghui Wang ◽  
Yulu Huang ◽  
Xiaoshuang Zhang ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Disease Models ◽  
Anti Inflammatory

Melatonin/polydopamine nanostructures for collective neuroprotection-based Parkinson's disease therapy

2020 ◽  
Vol 8 (5) ◽  
pp. 1345-1363 ◽  
Author(s):  
Anup K. Srivastava ◽  
Subhasree Roy Choudhury ◽  
Surajit Karmakar
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Dopaminergic Neurons ◽  
Disease Models ◽  
Disease Therapy ◽  
Apoptotic Effect ◽  
Anti Inflammatory

The bioinspired melatonin/polydopamine nanostructures confer superior neuroprotection in dopaminergic neurons via anti-oxidative, anti-inflammatory and anti-apoptotic effect in Parkinson's disease models.

scholarly journals Anti-inflammatory effects of BHBA in both in vivo and in vitro Parkinson’s disease models are mediated by GPR109A-dependent mechanisms

2015 ◽  
Vol 12 (1) ◽  
pp. 9 ◽  
Author(s):  
Shou-Peng Fu ◽  
Jian-Fa Wang ◽  
Wen-Jing Xue ◽  
Hong-Mei Liu ◽  
Bing-run Liu ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Disease Models ◽  
Anti Inflammatory

Peripheral Immunity, Immunoaging and Neuroinflammation in Parkinson’s Disease

2019 ◽  
Vol 26 (20) ◽  
pp. 3719-3753 ◽  
Author(s):  
Natasa Kustrimovic ◽  
Franca Marino ◽  
Marco Cosentino
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Immune System ◽  
Neurodegenerative Disorder ◽  
Neurodegenerative Process ◽  
Progressive Degeneration ◽  
Cytokine Levels ◽  
Inflammatory Phenotype ◽  
Immune Challenges

:Parkinson’s disease (PD) is the second most common neurodegenerative disorder among elderly population, characterized by the progressive degeneration of dopaminergic neurons in the midbrain. To date, exact cause remains unknown and the mechanism of neurons death uncertain. It is typically considered as a disease of central nervous system (CNS). Nevertheless, numerous evidence has been accumulated in several past years testifying undoubtedly about the principal role of neuroinflammation in progression of PD. Neuroinflammation is mainly associated with presence of activated microglia in brain and elevated levels of cytokine levels in CNS. Nevertheless, active participation of immune system as well has been noted, such as, elevated levels of cytokine levels in blood, the presence of auto antibodies, and the infiltration of T cell in CNS. Moreover, infiltration and reactivation of those T cells could exacerbate neuroinflammation to greater neurotoxic levels. Hence, peripheral inflammation is able to prime microglia into pro-inflammatory phenotype, which can trigger stronger response in CNS further perpetuating the on-going neurodegenerative process.:In the present review, the interplay between neuroinflammation and the peripheral immune response in the pathobiology of PD will be discussed. First of all, an overview of regulation of microglial activation and neuroinflammation is summarized and discussed. Afterwards, we try to collectively analyze changes that occurs in peripheral immune system of PD patients, suggesting that these peripheral immune challenges can exacerbate the process of neuroinflammation and hence the symptoms of the disease. In the end, we summarize some of proposed immunotherapies for treatment of PD.

Sign in / Sign up

Export Citation Format

Share Document